Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Revvity, Inc.

Alpha Analytical provides environmental testing and analysis services as a self-described expert in the field.

Alpha Analytical

Analytical Laboratories, Inc provides a full service, certified environmental laboratory capable of performing a variety of scientific services and testing.

Analytical Laboratories, Inc

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Avalon GloboCare Corp.

PerkinElmer provides analytical and laboratory services, testing solutions, and products across various sectors including environmental, industrial, food safety, and pharmaceuticals. The company focuses on enabling and accelerating science.

Metric
Company Name	Revvity, Inc.	Alpha Analytical	Analytical Laboratories, Inc	Avalon GloboCare Corp.
Symbol	RVTY			AVCO
MSH ID	COM:PERKINELMER	COM:ALPHALAB	COM:ANALYTICALLABSINC	COM:AVALON-GLOBOCARE
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Commercial & Professional Services	Commercial & Professional Services	Real Estate
Industry	Medical - Diagnostics & Research	Environmental Services	Laboratory Services	Real Estate - Services
Country	US	US	US	US
Stage				Post-IPO
Employee Count	11K			5
Website	perkinelmer.com	alphalab.com	analyticallabsinc.com	avalon-globocare.com
LinkedIn
Founders

Metric
Market Cap	13.16B	5.26M
Enterprise Value
Monthly Web Traffic		88
Web Traffic Growth		-0.85
Valuation
Raised Capital		20M

Metric
Revenue	2.75B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.17B
EBITDA	732.33M
Operating Income	300.56M
Net Income	179.50M
EPS	1.44
Diluted EPS	1.44
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.53
Operating Profit Margin	0.11
EBITDA Margin	0.27
Net Profit Margin	0.07
Return on Equity	0.02
Return on Assets	0.01
Return on Capital Employed	0.02

COM:PERKINELMER

PerkinElmer

Last Close

111.11

22/11 21:00

Market Cap

13.16B

Beta: -

Volume Today

1.14M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	72.51
P/B Ratio	1.67
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.79
EV Multiple	17.84

Metric
Days Sales Outstanding	84.15
Days Payables Outstanding	57.12
Days Inventory Outstanding	120.14
Operating Cycle	204.11
Cash Conversion Cycle	146.83
Asset Turnover	0.20

Metric
Operating Cash Flow	91.27M
Free Cash Flow	9.90M
Cash Flow to Debt	0.12
Operating Cash Flow/Sales	0.17
Free Cash Flow Yield	-0.00

Metric
Cash & Equivalents	914.37M
Accounts Receivable	-9.00M
Inventory	428.06M
Goodwill	6.53B
Debt to Capitalization	0.33
Debt to Assets	0.30
Current Ratio	2.01
Quick Ratio	1.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02
R&D to Revenue	0.08
SG&A to Revenue